Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Breast cancer is a systemic disease optimally treated by a multidisciplinary team

Nature Reviews Disease Primers volume 6, Article number: 30 (2020) Cite this article

Subjects

Summarizing a vast body of literature without losing meaningful information is a huge task, but the field — and patients — can benefit from these projects.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Harbeck, N. et al. Breast Cancer. Nat. Rev. Dis. Primers 5, 66 (2019).

    Article  Google Scholar 

  2. Burstein, H. J. et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 39, 1451–1557 (2019).

    Google Scholar 

  3. ABC5. Bridging the Gap. Advanced Breast Cancer http://www.abc-lisbon.org/ (2019).

Download references

Acknowledgements

The author thanks all co-authors of the Primer for their contributions as well as their enthusiasm and continued support, without which the Primer would not have been possible.

Author information

Authors and Affiliations

  1. Breast Center, Department of Gynecology and Obstetrics and CCCLMU, University of Munich (LMU), Munich, Germany

    Nadia Harbeck

Authors
  1. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nadia Harbeck.

Ethics declarations

Competing interests

N.H. reports honoraria for lectures and/or consulting from Agendia, Amgen, Astra Zeneca, BMS, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Odonate, Pfizer, Pierre-Fabre, Roche, Sandoz/Hexal and Seattle Genetics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harbeck, N. Breast cancer is a systemic disease optimally treated by a multidisciplinary team. Nat Rev Dis Primers 6, 30 (2020). https://doi.org/10.1038/s41572-020-0167-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41572-020-0167-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer